Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559163 | 0.84 | KDM4E (0.50) | CYP1A2KDM4EGRIA1GRIA2GRIA3 | |
| SCHEMBL9891078 | 0.79 | LMNA (0.51) | CYP1A2KDM4EGRIA1GRIA2GRIA3 | |
| SCHEMBL14480450 | 0.79 | KDM4E (0.47) | CYP1A2KDM4EGRIA1GRIA2GRIA3 | |
| SCHEMBL148953 | 0.79 | CYP3A4 (0.37) | CYP1A2KDM4ELMNAKMT2ACYP3A4 | |
| SCHEMBL9021896 | 0.79 | TK1 (0.56) | TK1 | |
| SCHEMBL4564516 | 0.79 | GRIA1 (0.49) | CYP1A2GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL17232952 | 0.78 | LMNA (0.47) | CYP1A2KDM4EGRIA1GRIA2GRIA3 | |
| SCHEMBL12410891 | 0.77 | TK1 (0.41) | CYP1A2KDM4EKMT2ACYP3A4CYP2D6 | |
| SCHEMBL11400618 | 0.77 | KDM4E (0.54) | CYP1A2KDM4EGRIA1GRIA2GRIA3 | |
| SCHEMBL1700458 | 0.76 | LMNA (0.51) | CYP1A2KDM4EGRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | CYP1A2 358/4885KDM4E 1986/4885GRIA1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.